• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sempra Appoints Jennifer M. Kirk to Board of Directors

    6/20/24 4:15:00 PM ET
    $MDT
    $SRE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Natural Gas Distribution
    Utilities
    Get the next $MDT alert in real time by email

    SAN DIEGO, June 20, 2024 /PRNewswire/ -- Sempra (NYSE:SRE) (BMV:SRE) today announced the appointment of Jennifer M. Kirk to the company's board of directors effective June 20, 2024. Kirk is currently the global controller and chief accounting officer of Medtronic plc (NYSE:MDT) and has deep executive experience in finance, accounting and capital market activities, including more than 20 years in the energy industry.

    Jennifer M. Kirk

    "Bringing new perspectives into the boardroom is a critical component of our effort to support the company's mission to build North America's premier energy infrastructure company," said Jeffrey W. Martin, Sempra chairman and CEO. "Our board of directors embody a diverse set of skills, experiences and viewpoints that help guide Sempra's corporate strategy and overall business success. Jennifer's strong accounting and finance experience, coupled with her understanding of the energy business, will be a great complement to the board as we advance our corporate strategy and oversee financial discipline, risk management and ethical practices."

    Before joining Medtronic, Kirk, 49, worked at Occidental Petroleum Corporation for more than two decades, serving in roles of increasing responsibility, including senior vice president of integration and value capture, and vice president, controller and principal accounting officer.

    Kirk serves on the board of directors of Republic Services, where she is chair of the audit committee. She holds a bachelor's degree in economics from UC Santa Barbara and a master's degree in business administration from California State University, Bakersfield.

    With the appointment of Kirk, Sempra will have 10 directors with three having been newly elected over the past five years, reflecting the company's commitment to periodic board refreshment to ensure fresh and diverse perspectives are present in the boardroom. Kirk will serve on the board's audit committee and the safety, sustainability and technology committee.

    About Sempra

    Sempra (NYSE:SRE) is a leading North American energy infrastructure company focused on delivering energy to nearly 40 million consumers. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving the energy resilience of some of the world's most significant economic markets, including California, Texas, Mexico and global energy markets. The company is recognized as a leader in sustainable business practices and for its high-performance culture focused on safety and operational excellence, as demonstrated by Sempra's inclusion in the Dow Jones Sustainability Index North America and in The Wall Street Journal's Best Managed Companies. More information about Sempra is available at sempra.com and on social media @Sempra.

     

    Sempra Logo (PRNewsfoto/Sempra)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sempra-appoints-jennifer-m-kirk-to-board-of-directors-302177421.html

    SOURCE Sempra

    Get the next $MDT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT
    $SRE

    CompanyDatePrice TargetRatingAnalyst
    DBA Sempra
    $SRE
    10/28/2025$115.00Overweight
    Wells Fargo
    DBA Sempra
    $SRE
    10/22/2025$106.00Buy
    BTIG Research
    DBA Sempra
    $SRE
    10/20/2025$101.00Equal Weight → Overweight
    Barclays
    DBA Sempra
    $SRE
    10/7/2025$105.00Outperform
    Evercore ISI
    Medtronic plc.
    $MDT
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    Medtronic plc.
    $MDT
    6/16/2025$110.00Outperform
    Leerink Partners
    DBA Sempra
    $SRE
    4/9/2025$93.00 → $70.00Neutral
    Citigroup
    DBA Sempra
    $SRE
    3/18/2025Buy → Hold
    Argus
    More analyst ratings

    $MDT
    $SRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

    NEW HOPE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company's participation appear below: 2025 Jefferies London Healthcare Conference – November 17-20, 2025 (London, UK) Management will host one-on-one meetings with investors on Tuesday, November 18. Piper 37th Annual Healthcare Conference – December 2-4, 2025 (New York, NY) M

    11/11/25 9:00:00 AM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates

    Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital from Medtronic and Ligand, as well as $30 million from TerumoInitiated patient enrollments in the Virtue Trial evaluating Virtue® Sirolimus AngioInfusion™ Balloon ("Virtue SAB") trial versus commercially available paclitaxel-coated balloon Demonstrated partnership-driven business model execution with expanded strategic collaboration with Medtronic and new right of first refusal agreement with Terumo NEW HOPE, Pa., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO,

    11/10/25 4:10:38 PM ET
    $LGND
    $MDT
    $OBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medicinal Chemicals and Botanical Products

    Sempra Declares Common Dividend

    SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Sempra (NYSE:SRE) today announced that its board of directors has declared a $0.645 per share quarterly dividend on the company's common stock, which is payable Jan. 15, 2026, to common stock shareholders of record at the close of business on Dec. 11, 2025. About SempraSempra is a leading North American energy infrastructure company focused on delivering energy to nearly 40 million consumers. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving the energy resilience of some of the world's most significant economic markets, including California, Texas, Mexico and global energy markets. The company is reco

    11/6/25 7:41:00 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    SEC Filings

    View All

    SEC Form 10-Q filed by DBA Sempra

    10-Q - SEMPRA (0001032208) (Filer)

    11/5/25 4:10:30 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    DBA Sempra filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SEMPRA (0001032208) (Filer)

    11/5/25 10:51:06 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Medtronic plc. filed SEC Form 8-K: Leadership Update

    8-K - Medtronic plc (0001613103) (Filer)

    11/3/25 5:21:46 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    $SRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Sempra Energy with a new price target

    Wells Fargo initiated coverage of Sempra Energy with a rating of Overweight and set a new price target of $115.00

    10/28/25 8:19:49 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    BTIG Research initiated coverage on Sempra Energy with a new price target

    BTIG Research initiated coverage of Sempra Energy with a rating of Buy and set a new price target of $106.00

    10/22/25 8:03:07 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Sempra Energy upgraded by Barclays with a new price target

    Barclays upgraded Sempra Energy from Equal Weight to Overweight and set a new price target of $101.00

    10/20/25 8:24:50 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Corp Affairs and HR Larroque Alexander Lisa sold $400,001 worth of shares (4,322 units at $92.55), decreasing direct ownership by 28% to 11,325 units (SEC Form 4)

    4 - SEMPRA (0001032208) (Issuer)

    11/7/25 5:05:15 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    SEC Form 4 filed by Director Sagara Kevin C.

    4 - SEMPRA (0001032208) (Issuer)

    10/2/25 6:12:36 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    SEC Form 4 filed by Director Mears Michael N

    4 - SEMPRA (0001032208) (Issuer)

    10/2/25 6:10:46 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Ferrero Pablo bought $184,496 worth of shares (2,600 units at $70.96), increasing direct ownership by 20% to 15,649 units (SEC Form 4)

    4 - SEMPRA (0001032208) (Issuer)

    3/17/25 9:10:57 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Director Conesa Andres bought $100,156 worth of shares (1,400 units at $71.54), increasing direct ownership by 7% to 21,668 units (SEC Form 4)

    4 - SEMPRA (0001032208) (Issuer)

    3/17/25 9:10:19 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Kayne Anderson Energy Infrastructure Fund Announces Appointment of New Independent Directors

    HOUSTON, May 27, 2025 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the "Company" or "KYN") announced today the appointments of Holli C. Ladhani and Michael N. Mears as independent directors of the Company, effective immediately. Following the retirements of Anne K. Costin and Albert L. Richey earlier this year, the appointments of Ms. Ladhani and Mr. Mears return the Company's Board to eight members, seven of whom are independent. Holli C. Ladhani is an experienced executive and board director in the energy, chemicals, power, and infrastructure sectors. Ms. Ladhani most recently served as President, Chief Executive Officer, and a member of the board of directors of

    5/27/25 4:15:00 PM ET
    $DVN
    $KYN
    $PWR
    Oil & Gas Production
    Energy
    Finance/Investors Services
    Finance

    $MDT
    $SRE
    Financials

    Live finance-specific insights

    View All

    Sempra Declares Common Dividend

    SAN DIEGO, Nov. 6, 2025 /PRNewswire/ -- Sempra (NYSE:SRE) today announced that its board of directors has declared a $0.645 per share quarterly dividend on the company's common stock, which is payable Jan. 15, 2026, to common stock shareholders of record at the close of business on Dec. 11, 2025. About SempraSempra is a leading North American energy infrastructure company focused on delivering energy to nearly 40 million consumers. As owner of one of the largest energy networks on the continent, Sempra is electrifying and improving the energy resilience of some of the world's most significant economic markets, including California, Texas, Mexico and global energy markets. The company is reco

    11/6/25 7:41:00 PM ET
    $SRE
    Natural Gas Distribution
    Utilities

    ONCOR REPORTS THIRD QUARTER 2025 RESULTS

    DALLAS, Nov. 5, 2025 /PRNewswire/ -- Oncor Electric Delivery Company LLC (Oncor) today reported net income of $380 million for the three months ended September 30, 2025, compared to net income of $324 million in the three months ended September 30, 2024. The increase in net income of $56 million was driven by overall higher revenues primarily attributable to updated interim rates to reflect increases in invested capital, an increase in other regulated revenues recognized related to Oncor's System Resiliency Plan (SRP) and the Unified Tracker Mechanism (UTM), and customer growth, partially offset by higher interest expense and depreciation expense associated with increases in invested capital

    11/5/25 8:00:00 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    Sempra Reports Third-Quarter 2025 Results

    Advances 45% Equity Sale at Sempra Infrastructure PartnersExpect 30%+ Increase in Oncor's 5-Year Capital Plan SAN DIEGO, Nov. 5, 2025 /PRNewswire/ -- Sempra (NYSE:SRE) today reported third-quarter 2025 earnings, prepared in accordance with Generally Accepted Accounting Principles (GAAP), of $77 million or $0.12 per diluted share, compared to third-quarter 2024 GAAP earnings of $638 million or $1.00 per diluted share. On an adjusted basis, third-quarter 2025 earnings were $728 million or $1.11 per diluted share, compared to $566 million or $0.89 per diluted share in 2024.   "We are pleased with another solid quarter of financial performance," said Jeffrey W. Martin, chairman and CEO of Sempra

    11/5/25 7:55:00 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    $MDT
    $SRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DBA Sempra

    SC 13G - SEMPRA (0001032208) (Subject)

    11/8/24 10:52:39 AM ET
    $SRE
    Natural Gas Distribution
    Utilities

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by DBA Sempra (Amendment)

    SC 13G/A - SEMPRA (0001032208) (Subject)

    2/13/24 4:56:00 PM ET
    $SRE
    Natural Gas Distribution
    Utilities